Objectives. To assess the prevalence, extent, progression, functional impact and mortality of interstitial lung disease (ILD) in a nationwide unselected MCTD cohort.
Introduction
MCTD is a chronic, immune-mediated disorder defined by the combined presence of serum anti-RNP antibodies and selected clinical features of SSc, SLE, RA and PM/DM. The entity was first described by Sharp et al. in 1972 [1, 2] . Since then it has been debated whether MCTD is a distinct disease, an overlap syndrome or a transient phase before developing into another CTD [3, 4] . Genetic studies from Europe [57] and Asia [8] support the notion that MCTD is a distinct disease. Interstitial lung disease (ILD) is a major cause of morbidity and mortality in the CTDs, particularly in SSc [9, 10] and PM/DM [11] . In MCTD prevalence figures from different cohorts have ranged from 47 to 78% [12, 13] . Previously, our research group investigated the prevalence and incidence of MCTD between the years of 2005 and 2008. One hundred and forty-seven patients were included in the nationwide MCTD cohort [14] . Analyses of lung high-resolution CT at study inclusion found that reticular pattern was generally present in the basal zones and the most common abnormality, resembling the pattern seen in SSc [15] . Studies from other countries have reported different CT findings. In a study on 41 MCTD patients from Japan, interlobular septal thickening was the predominant pattern [16] , while a Hungarian study reported that ground glass attenuation was highly frequent [17] . In a recent report from Brazil the most common patterns were ground glass and reticular changes [18] . Histological descriptions of MCTD-related lung pathologies are scarce. Hajas et al. [12] reviewed lung biopsies from 16 MCTD patients where the ILD diagnosis could not be resolved by imaging alone. All these 16 patients had findings compatible with nonspecific interstitial pneumonitis, where 11 had cellular interstitial pneumonitis with little or no fibrosis and the remaining 5 had significant fibrosis.
Data on the course and outcome of ILD in MCTD are limited. Bodolay et al. [17] reported mild fibrosis in the majority of MCTD patients, but did not present how this was evaluated. Kawano-Dourado et al. [18] recently presented serial CT analyses in 37 MCTD patients followed at a tertiary centre, and showed that the median percentage ILD score in the lower lobes increased from 7.5 to 11.3% over 10 years, indicating restricted disease progression. There are no larger longitudinal studies on the overall progression of ILD in unselected MCTD cohorts, and outcome risk factors are needed. Predictive factors for progressive ILD have been studied in SSc [19] but remain unknown in MCTD. ILD is known to predict mortality in SSc [19] and PM/DM [11, 2022] while the effect of ILD on mortality has not been established in MCTD cohorts.
Here, we present a long-term observational study of the unselected, nationwide Norwegian MCTD cohort, with serial CT and pulmonary function test analyses. The aim of this study was to examine the prevalence, extent, progression and functional effect of ILD in MCTD. We also wanted to identify predictive factors of ILD progression in MCTD, aiming to aid the clinician in identifying MCTD patients at risk of deteriorating lung function. Finally, we wanted to estimate the effect of ILD on mortality in MCTD.
Methods

Patient population
The Norwegian nationwide MCTD cohort recruited patients from Departments of Rheumatology in Norway during the years of 200508 [15] with the following inclusion criteria: age above 18 years; fulfillment of at least one of the three criteria sets of MCTD, the modified Sharp's criteria [1] , the criteria of Alarcó n-Segovia and/or Kasukawa [23] ; and exclusion of another CTD. In the present study we included all patients from the nationwide MCTD cohort where baseline CTs were attainable for assessment (n = 135), encompassing all 126 patients included in the evaluation of ILD prevalence and severity from 2012 [15] as well as nine additional patients from the nationwide MCTD cohort.
Clinical data
Clinical parameters included symptoms and signs included in the three classification criteria as well as smoking history, medications and vital status. The clinical parameters were recorded at two time points: baseline and follow-up. Baseline was defined as study entry. Myositis was confirmed by muscle biopsy and/or electromyogram and CK elevation. Smokers had smoked >1 cigarette a day for >1 year. Precapillary pulmonary hypertension was defined according to the updated European Society of Cardiology criteria by mean pulmonary artery pressure 525 mmHg and pulmonary wedge pressure 415 mmHg by right-sided heart catheterization at rest [24] . Vital status at the end of the study was obtained from the National Population Register of Norway.
Acquisition and analysis of CT images CT lung examination was included in the study protocol at baseline and at follow-up. High-resolution CT images were obtained with the patient in the supine position, during breath-holding and inspiration. The images were reconstructed at 11.25 mm section thickness with 10-mm intervals and at 2.5-mm section thickness reformatted in the axial, coronal and sagittal planes. Images were reviewed on a picture archiving and communication system screen in consensus and in random order by two specialist chest radiologists. The observers evaluated the presence and extent of ILD. These findings included reticular pattern, ground glass attenuation, traction bronchiectasis, interlobular septal thickening and airspace consolidations according to the CT criteria of ILD recommended by The Nomenclature Committee of the Fleischner Society [25] . Although the term honeycombing is common in radiological studies, the definition is not standardized [26] . Reticular pattern (i.e. the coarseness of fibrosis) was therefore graded as follows: grade 1, fine intralobular reticular pattern without evident cysts; grade 2, predominantly micro-cystic reticular pattern involving air spaces 44 mm in diameter; and grade 3, a predominantly macro-cystic reticular pattern with air spaces >4 mm in diameter. If ground glass attenuations were superimposed on a reticular pattern, the abnormality was recorded as being reticular. When a grade 1 pattern was superimposed on a grade 2 pattern, the abnormality was recorded as grade 2. If different types of reticular patterns were present in different lung zones of an individual patient, both pattern types were recorded. Abnormal CT findings of ground glass attenuation and reticular patterns grades 13 were defined as ILD. The distribution of disease was reviewed in four lung zones: zone 1, above the aortic arch; zone 2, between the aortic arch and at the level of the carina; zone 3, between the level of the carina and the level of the inferior pulmonary veins; and zone 4, below 1 cm above the top of the right hemidiaphragm. The extent of involvement was evaluated independently for each zone and each zone was assigned a percentage of the lung parenchyma that showed evidence of ILD. The total extent of disease in each patient was added in the four lung zones and expressed as a percentage of total lung volume (TLV). ILD progression was defined as a disease extension as a percentage of TLV and stable ILD was defined as no disease extension as a percentage of TLV between baseline and follow-up. Minimal time between the baseline and follow-up CT was 12 months. Follow-up CT scans were available in 119 of 135 patients. Clinical information about the 16 patients where follow-up lung CT examination was not available can be found in supplementary Table S1 , available at Rheumatology Online. The CT scans were subjectively assessed for possible oesophageal motility disorders. Substantial distension was recorded when columns of air and distension larger than doubling the oesophageal wall thickness was identified.
Pulmonary function test analyses
The pulmonary function test analyses were performed within 8 weeks of the corresponding CT and performed according to the American Thoracic Society/European Respiratory Society guidelines [27] , using an automated V max V6200 system (SensorMedics, VIASYS Respiratory Care Inc, Yorba Linda, CA, USA). Recorded variables were the percentage of predicted value of full vital capacity (FVC% pred) and the percentage of predicted value of diffusing capacity of the lung for carbon monoxide (DLCO% pred).
Autoantibody analyses
Serum levels of anti-RNP autoantibody at baseline and follow-up in addition to anti-ro52 antibodies at baseline were determined by line immunoassay (ANA Profile 5 Euroline Blot test kit, Euroimmun, Lü beck, Germany). Strips were scanned to obtain optical density values according to the kit instructions. Anti-ro52 antibodies optical density values of 510 were recorded as positive.
Statistical analyses
The data were presented as means (S.D.) or median and interquartile range (IQR) depending on the level of resemblance to the normal distribution. Comparisons of groups were performed appropriately by chi-square test, Fisher's exact test, or one-way ANOVA with post hoc comparisons by Tukey's test or the KruskalWallis test and MannWhitney U test. Cox regression analyses were used to find predictive factors of lung disease progression. Using a manual backward elimination procedure, variables at a significance level of P < 0.25 in the univariable analyses were considered a candidate for the multivariable model. The prediction was quantified by the hazard ratio (HR) with its 95% CI. Patients were followed from the date of inclusion in the cohort until death or end of follow-up on 30th of April 2016. KaplanMeier survival curves were used to examine differences in survival between patients with and without disease compromising 55% and 510% of TLV. The log-rank test was used to assess differences. The proportional hazard assumptions were tested by plotting the logarithm of the integrated hazards (loglog survival plots). To estimate the total effect of ILD on mortality with minimal bias, we performed multivariable cox regression analyses adjusting for variables selected from the directed acyclic graph presented in supplementary Fig. S1 , available at Rheumatology Online [28] . Data extraction and analyses were conducted using SPSS Statistics version 22 (IBM Corp., Armonk, NY, USA) and STATA version 22 (StataCorp, College Station, TX, USA).
Ethical approval
The study was approved by the Norwegian Regional Committee for Medical and Health Research Ethics and conducted in accordance with the guidelines of the Helsinki declaration. All patients had given informed written consent to participate in the study.
Results
Prevalence, extent and distribution Serial lung CT images available for evaluation were retrieved in 119 of 135 patients. There were no significant differences found in terms of gender, age at diagnosis, disease duration at baseline or classification criteria when comparing these 119 patients against the 16 patients with missing follow-up. Mean (S.D.) age at diagnosis in the 135 patients with baseline CT data was 35 (16) years and mean (S.D.) disease duration was 9 (8) years. The Alarcó n-Segovia criteria were met by 90%, 97% fulfilled the Sharp criteria and 86% fulfilled the Kasukawa criteria. The mean (S.D.) time between baseline and follow-up CT was 6.4 (2.0) years. CT findings compatible with ILD were present at baseline in 40% and at follow-up in 41% of the patients (Table 1 ). There were only two new cases of ILD during the study observation. Median (IQR) extent of lung disease increased from 5 (8)% of TLV at baseline to 7 (17)% of TLV at follow-up ( Table 1 ). The extension was generally slow, apparent by the number of patients with disease involving 55, 10 and 20% of TLV at follow-up compared with baseline (Table 1) . Distribution analyses demonstrated lung disease to be present largely in the lower lung lobes, but about half of the patients with lung disease did have findings of ILD in the upper part of the lungs (i.e. in zone 1: see 'Methods' section for details) ( Table 1) . Fine reticular pattern (grade 1) was the most common abnormality; however, macro-cystic reticular pattern (grade 3) covered a larger area of the lungs in the patients where this pattern was evident (Table 1) .
Progression
Patients were stratified in three groups: group 1, no ILD (n = 70); group 2, stable ILD (n = 26); and group 3, ILD progression (n = 23) ( Table 2 ). The median (IQR) annual disease progression in group 3 was 1.1 (2)% of TLV.
www.rheumatology.oxfordjournals.org Compared with group 1 fewer patients had arthritis and anti-RNP titres were higher at baseline and at follow-up in group 3 ( Table 2 ). Frequency of cases meeting the Alarcó n-Segovia criteria was lowest in group 3. Group 2 (stable ILD) differed from the two other groups by a higher occurrence of patients with dilated oesophagus.
Functional impact
The extent of ILD at baseline CTs was greater in group 3 than group 2, although not significantly ( Table 2 ). Figure 1 illustrates the effect of ILD on mean lung function test results. FVC% pred differed significantly in group 3 compared with group 2 (P = 0.002) and group 1 (P < 0.001) at baseline and at follow-up (both P < 0.001). Group 3 differed significantly in lower mean values of DLCO% pred compared with group 1 (P < 0.001) but not group 2 at baseline, while at follow-up DLCO% pred was significantly lower in group 3 compared with both group 1 (P < 0.001) and group 2 (P = 0.001). FVC% pred in group 2 did not differ significantly from group 1 at baseline or at follow-up. DLCO% pred in group 2 differed significantly from group 1 at baseline (P = 0.003) but not at follow-up.
Treatment
Analyses of immune-modulating treatments did not indicate clear differences between groups 13, except for higher accumulated frequencies of AZA usage in patients with stable ILD (group 2) (supplementary Table S2 , available at Rheumatology Online).
Predictors of progression
Multiple Cox regression analyses revealed that the strongest predictive factors at baseline for ILD progression at follow-up were male gender, elevated anti-RNP titre, the presence of anti-ro-52 antibodies and absence of arthritis when adjusting for baseline lung disease and age (Table 3) . A rise of 50 U/ml in anti-RNP titre resulted in 50% increased risk of ILD progression (95% CI: 1.1, 2.0; P = 0.008), while a history of arthritis reduced the risk by 80% (95% CI: 0.1, 0.6; P = 0.004). The risk of ILD progression was 4-fold in male patients (95% Cl: 1.4, 11.5; P = 0.011) and >3-fold in patients with anti-ro52 antibodies (95% Cl: 1.2, 10.2; P = 0.023). According to Harrell's C index, patient outcomes were accurately predicted by this model 91% of the time. 
ILD in MCTD
Effect on all-cause mortality The effect of ILD on mortality was evaluated by dividing the patient cohort in two subsets: disease extent <5% (n = 108), and 55% of TLV (n = 27) and <10% (n = 122) and 510% (n = 13) of TLV. The 5-year cumulative survival rates for <5% and 55% disease of TLV were 94% (95% CI: 88, 98%) and 82% (95% CI: 61, 92%), respectively. The 10-year cumulative survival rates were 87% (95% CI: 79, 92%) and 70% (95% CI: 49, 84%; log rank P = 0.015) (Fig. 2) . The 5-year cumulative survival rates for <10% and 510% disease of TLV were 93% (95% CI: 85, 95%) and 77% (95% CI: 44, 92%), respectively, and the 10-year cumulative survival rates were 86% (95% CI: 78, 91%) and 60% (95% CI: 29, 81%), respectively (log rank P = 0.01). Cox regression univariable analyses revealed that having disease extending 55% of TLV was associated with 3-fold increased risk of death (HR: 2.9, 95% CI: 1.2, 7.0; P = 0.020), while having disease involving 10% of TLV increased the risk by almost fourfold (HR: 3.5, 95% CI: 1.3, 9.5; P = 0.015) ( Table 4) . A disease extension of 1% of TLV was associated with increased risk of death (HR: 1.1, 95% CI: 1.0, 1.1; P < 0.001) ( Table 4 ). The total effect of % ILD extent on all-cause mortality (see supplementary Fig. S1 , available at Rheumatology Online) was similar after adjustments to smoking, gender, disease duration and age (Table 4) .
Discussion
ILD is frequently reported in MCTD cohorts and studies of the long-term clinical impact of these changes are necessary to assist rheumatologists in the management of MCTD. Here, we found that 19% of patients in our nationwide, unselected MCTD cohort had ILD progression on CT, where the mean (S.D.) disease duration was 17 (8) years. The annual progression is modest, but results in deteriorating lung function in this relatively young patient population. Based on the presenting, high resolution, long-term observational study in addition to comparable work on smaller patient populations [17, 18] and crosssectional studies [2] , it appears reasonable to draw the following conclusions: interstitial lung changes occur frequently in MCTD; ILD extent in MCTD is typically modest; approximately half of the patients with established lung disease have progression; the progression is generally slow, but appears to continue several years after diagnosis causing deteriorating lung function; a subset of patients, in our study 10%, had developed extensive ILD (>20% of TLV); and, finally, ILD is associated with increased risk of mortality, and should therefore be regarded as a major complication in MCTD.
Interestingly we found that increasing anti-RNP antibody titres at baseline was a strong predictor of ILD progression. Greidinger et al. [29] found anti-70K antibodies to be strongly correlated with lung disease in 70K immunized mice. Notably, in a recent study on juvenile MCTD our colleagues found increased anti-RNP antibody titres in 
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KaplanMeier curves for interstitial lung disease involving 55% and <5% of total lung capacity patients with active disease [30] corresponding to previous findings of Burdt et al. [31] . The presence of anti-ro-52 antibodies was recently found to be associated with ILD in our MCTD cohort [32] . We here present that the presence of anti-ro-52 antibodies is additionally a predictor of ILD progression in MCTD. Furthermore, we found arthritis to be protective of lung disease progression, possibly indicating that MCTD patients with more SLE-like features are less likely to develop severe lung disease. Previous studies of MCTD have found oesophageal dysmotility to be related to ILD [18, 33] . We did not examine dysmotility directly but observed that patients with distended oesophagus on CT were significantly more frequent in patients with ILD (data not shown).
To our knowledge, this is the first MCTD study to show that the extent of ILD has an effect on all-cause mortality after adjustments to possible confounders in multivariable analyses. The strengths of this study were that the MCTD patients were derived from a large unselected nationwide cohort and that CTs were systematically analysed at baseline and at follow-up. The present study is the largest dataset of MCTD patients with systematically analysed CTs at two time points. The study has a longitudinal design with consistent data at baseline and at follow-up allowing us to assess a number of relevant parameters in univariable and multivariable analyses. The large number of attained baseline lung CT examinations is a strength of this study, yet a limitation of this study is that a follow-up CT was not accessible in all 135 patients. However there were no significant differences found between the patient groups with and without follow-up lung CT. A possible limitation of this study is the relatively low number of outcomes in the multivariable analyses. However, studies have shown that one can adjust for more variables per number of outcomes than previously assumed [34] and the associations found in the presenting study are strong and significant in both univariable and multivariable models. Due to limited number of events; and lack of data on cause of death, we did not have the possibility to assess whether any of the deaths were directly or indirectly related to ILD.
In conclusion ILD in MCTD is common; it generally involves a modest proportion of TLV with basal distribution. Stable lung disease and slow disease progression is equally present. The risk factors of ILD progression are male gender, high anti-RNP antibody titre, presence of anti-ro-52 antibodies and no prior arthritis. ILD is associated with increased risk of mortality in our longterm observational study. Our findings can hopefully aid rheumatologists in identifying MCTD patients at risk of deteriorating lung disease and reduced survival. Vriables included in the multivariable models: age at baseline, smoking, disease duration at baseline and gender. TLV: total lung volume.
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